|Written||2014-11||Marta Mellai, Davide Schiffer|
|Centro Ricerche di Neuro-Bio-Oncologia / Fondazione Policlinico di Monza / Consorzio di Neuroscienze, Universita di Pavia, Via Pietro Micca 29, 13100, Vercelli (Italy)|
|Abstract|| Epithelial membrane protein 3 (EMP3) has recently been proposed as a candidate tumor suppressor gene (TSG) for some kinds of solid tumors. EMP3 down-regulation has been explained by its epigenetic silencing through aberrant hypermethylation of the promoter region.
EMP3 repression in cancer seems to be an organ-specific phenomenon, common in neuroblastoma and gliomas, relatively common in breast cancer, and rare in esophageal squamous cell carcinoma (ESCC). Among cancer-derived cell lines, it prevails in neuroblastoma, breast cancer and ESCC whereas it is rare in glioma, non-small cell lung carcnoma (NSCLC), gastric and colon cancer-derived cell lines.
EMP3 expression level is associated with clinical prognosis in neuoblastoma, ESCC, NSCLC and upper urinary tract urothelial carcinoma. In contrast, EMP3 expression may be a novel marker of tumor aggressiveness in breast cancer whereas in gliomas, EMP3 represssion by aberrant hypermethylation has a prognostic signifcance. In both tumor types, however, alternative mechanisms to the EMP3 epigenetic silencing may exist to explain EMP3 down-regulation.
Moreover, EMP3 may be involved in the prostate cancer suscpetibility.
|Keywords||Epithelial membrane protein 3 (EMP3), tumor suppressor gene, solid tumors, promoter hypermethylation, prognosis.|
(Note : for Links provided by Atlas : click)
|Location||19q13.33 [Link to chromosome band 19q13]|
|Location_base_pair||Starts at 48325372 and ends at 48330553 bp from pter ( according to hg19-Feb_2009) [Mapping EMP3.png]|
|Local_order||EMP3 is located centromeric to TMEM143 (transmembrane protein 143) and telomeric to CCDC114 (coiled-coil domain-containing protein 114).|
|Data from Atlas, Mitelman, Cosmic Fusion, Fusion Cancer, TCGA fusion databases with official HUGO symbols (see references in chromosomal bands)|
|TENM4 (11q14.1) / EMP3 (19q13.33)|
|Note||EMP3 is a hydrophobic membrane glycoprotein belonging to the PMP22 protein family. It displays a high degree of cross-species conservation in its nucleotide and protein sequence.|
|Note|| A human EMP3 cDNA was first identified by homology screening of databases (Ben-Porath and Benvenisty, 1996; Taylor and Suter, 1996). EMP3 belongs to the peripheral myelin protein 22-kDa (PMP22) gene family of small hydrophobic membrane glycoproteins (Taylor et al., 1995). It includes four closely related members (PMP22, EMP1, EMP2 and EMP3), as well as the additional and more distant member MP20. The amino acid sequence homology with PMP22, EMP1, EMP2 and MP20 is 41, 33, 38 and 23%, respectively, with the highest homology in the transmembrane domains (TMDs). The genomic structure, as well as the putative four TMD structure (included a PMP22 Claudin domain) are highly conserved among family members.
Functionally, the PMP22 gene family may control cell proliferation, cell differentiation and cell death. Remarkable, mutations in the PMP22 gene are responsible for various hereditary peripheral neuropathies in both humans and mice (Leal et al., 2001).
The human EMP3 gene maps on chromosome 19q13.33 (Lieher et al., 1999). The homologous gene in mouse maps on chromosome 7 (Ben-Porath et al., 1998).
|Graphical scheme of the human EMP3 gene. Grey boxes correspond to untranslated and black boxes to translated regions (all in scale). Arrows indicate the ATG and the stop codons, respectively.|
|Description|| The genomic size of the human EMP3 gene is of 5.183 Kb, localized from 48325372 to 48330553. |
The 5'-UTR region contains a CpG island (62 CpG dimers) localized around the transcription start site (from -13 to +241 bp) (GenBank reference sequence NM_001425) (Alaminos et al., 2005). Regulatory transcription factor binding sites in the promoter region are COUP-TF1, STAT1, Bach2, Rel4, HNF-4alpha1, E47, AREB6, RORalpha1, HEN1 and COUP-TF.
|Transcription||The gene is composed of five exons, including a non-coding exon 1, and produces at least nine different alternative splicing isoforms.|
|Pseudogene||No known pseudogenes.|
|Note||EMP3 is a 163-amino acid membrane glycoprotein.|
|Schematic view of the predicted structure of the multi-pass human EMP3 protein in a lipid bilayer. The Y-shape symbol indicates the putative N-linked carbohydrate sites in the first extracellular loop at Asn47 and Asn56 residues. The four hydrophobic TMDs (from 4 to 24, 66 to 86, 100 to 120 and 139 to 159 amino acid residues) and the PMP22 Claudin domain (from 20 to 156 residues) are shown with respect to the intracellular and extracellular sides of the membrane (Jetten and Suter, 2000). The molecular weight is of 18.429 kDa.|
|Description||EMP3 belongs to the PMP22 protein family and shares with its members structural and functional homologies.|
|Expression||Promimently expressed in fetal lung, liver and kidney, but relatively weakly expressed in both fetal and adult brain. In adult, it is ubiquitariously expressed in various normal tissues including lung, liver, ovary, small intentistine, colon, thymus, kidney, pancreas, heart and placenta with the highest expression in peripheral blood leukocytes (Taylor and Suter, 1996).|
|Localisation||Localised in the cell-membrane and cytoplasm.|
|Function|| The function of the EMP3 protein is largely unknown but it may be involved in the following physiological processes.|
On the basis of its sequence similarity to EMP1, it may be involved in the regulation of cell proliferation (Bolin et al., 1997).
The higher expression levels in fetal brain, lung and kidney compared to the respective adult counterparts suggest a role in the developmental regulation, especially in neuronal development (Bolin et al., 1997).
It may control the regulation of cell growth, differentiation and death, since its overexpression results in cell blebbing in embryonic kidney cell cultures and in the activation of the apoptosis pathway (Wilson et al., 2002).
In peripheral nervous system, it may regulate Schwann cell proliferation after injury and cell-cell interactions in active myelination (Bolin et al., 1997).
It may have possible roles in hematopoietic system (Bolin et al., 1997).
|Homology|| Comparative sequence analysis revealed the remarkable conservation of the EMP3 primary sequence. The EMP3 gene is present in the common ancestor of chordates and it is conserved in chimpanzee, Rhesus monkey, dog, cow, mouse, rat, zebrafish and frog. |
The PMP22 gene family probably evolved as result of a chromosome duplication event and divergence (Ben-Porath et al., 1998). Paralogs are PMP22, EMP1 and EMP2. Seventy-four organisms have orthologues with the human EMP3 gene.
|Note|| Neither causative nor functional mutations reported. |
Eighteen human genomic variants from 12 studies described, three of which (nsv531627, nsv531628 and nsv531629, all copy number gains) with pathogenic clinical significance since associated to global developmental delay and seizure (Miller et al., 2010; Kaminsky et al., 2011).
In mouse, a single nucleotide polymorphism (SNP) is responsible for the reciprocal H4 minor histocompatibility alloantigens in the MHC-bound peptide derived from EMP3 and presented by the MHC class I molecule. The C>T nucleotide change results in the amino acid substitution from Thr (H4a, SGTVYIHL) to Ile (H4b, SGIVYIHL) in the minimal antigenic epitope SGIVYIHL (SYL8) derived from H4(b) (Yadav et al., 2003; Luedtke et al., 2003)
|Germinal||No germinal mutations described.|
|Somatic||A total of eight putative somatic mutations reported in public databases. Six are missense substitutions identified in lung adenocarcinoma (p.Val7Leu), in colon adenocarcinoma (p.Val21Met, confirmed somatic), in squamous cell lung carcinoma (SCLC) (p.A22T, confirmed somatic), in endometrioid carcinoma (p.Cys34Arg), in esophageal carcinoma (p.Ala65Val) and in large intestine adenocarcinoma (p.Met70Val). A p.Asn47Asn synonimous substitution detected in colon adenocarcinoma and a p.Gly133fs*>31 frameshift deletion in endometrioid carcinoma. When not specificied, variants are of unknown origin.|
5. Implicated in
|Entity||Neuroblastoma / phaeochromocytoma|
|Note|| By methylation-specific PCR (MS-PCR) and direct bisulphate DNA sequencing, EMP3 hypermethylation is common in both tumor tissue (24-68.4%) and neuroblastoma cell lines (33.3%). It occurs with concomitant downregulation of EMP3 protein expression in all clinical samples and in only 33.3% of neuroblastoma cell lines (Alaminos et al., 2005; Margetts et al., 2008). EMP3 hypermethylation is associated with poor survival at two-year follow-up and with an high mortality rate (Alaminos et al., 2005).|
In contrast, it is a rare event in sporadic (7.1%) and adult VHL-associated (6.1%) phaeochromocytomas (Margetts et al., 2008).
|Entity||Brain tumors / gliomas|
|Note|| By MS-PCR, EMP3 hypermethylation is an early epigenetic event in gliomagenesis. It is common in pure (63%) and mixed (70%) oligodendroglial tumors in comparison to astrocytic ones (18%). It prevails in grade II (71.4%) upon grade III (44.7%) gliomas, and in secondary (89%) upon primary GBMs (17%) (Alaminos et al., 2005; Li et al., 2007; Kunitz et al., 2007; Mellai et al., 2013). Not found in GBM cell lines (Ernst et al., 2009). |
Aberrant hypermethylation correlates with reduced mRNA expression and lack of EMP3 protein expression. It is strongly associated with IDH1/IDH2 somatic mutations in astrocytic and oligodendroglial tumors and inversely correlated with EGFR gene amplification. In oligodendrogliomas, it is also associated with loss of the 19q13.3 locus and with total 1p/19q co-deletion (Tews et al., 2006; Mellai et al., 2013), with prognostic significance on patient overall survival (Kunitz et al., 2007; Mellai et al., 2013).
The EMP3 gene belongs to the glioma CpG island methylator phenotype (G-CIMP) (Noushmehr et al., 2010), that identifies a distinct molecular glioma subclass, prevalent in low-grade tumors and associated with IDH1/2 mutations and with improved patient survival (Laffaire et al., 2011).
No tumor-specific mutations identified on 132 glioma patients, except for the SNPs rs4893 (p.Ile125Val, exon 5) and rs11671746 (3'-UTR) in four patients (Kunitz et al., 2007).
|Entity||Esophageal squamous cell carcinoma (ESCC)|
|Note||By MS-PCR, EMP3 hpermethylation is rare in tumor tissue (6%) but frequent in ESCC cell lines (75%), with an inverse correlation with mRNA expression levels (Fumoto et al., 2009a). Low EMP3 expression is associated with poor prognosis after recurrence, suggesting that EMP3 inactivation may confer an advantage for tumor growth only at late stage of disease.|
|Note|| By RT-PCR, EMP3 mRNA expression is significantly higher in primary tumors than in normal breast tissue. It correlates with the histologic grade III, lymph node metastatis and Her-2 expression in human mammary luminal epithelial cells (Mackey et al., 2003 ; Zhou et al., 2009). It may be a novel marker of tumor aggressiveness (Zhou et al., 2009). |
By MS-PCR, EMP3 hypermethylation occurs occasionally in primary tumor tissue (36.5%) without association with mRNA expression levels. In breast cancer cell lines, EMP3 mRNA is frequently repressed in both invasive (70%) and non-invasive phenotype (75%). Promoter hypermethylation may explain mRNA repression in almost all the non-invasive phenotype and in only a part of the invasive phenotype (Evtimova et al., 2003).
|Entity||Non-small cell lung cancer (NSCLC)|
|Note|| By Western blotting, EMP3 expression in tumor tissue is signifcantly lower than in normal lung tissue, correlates with the p-TNM stage and negatively with the proliferation index Ki-67. EMP3 may be a TSG at late stage of disease and a potential marker of prognosis in lung patients (Xue et al., 2013).|
In lung cell lines, EMP3 is repressed with partial CpG hypermethylation in 11.1% of cases (Fumoto et al, 2009a).
|Entity||Upper urinary tract urothelial carcinoma|
|Note||At mRNA and protein level, EMP3 overexpression promotes in vitro tumor cell proliferation and migration by activation of the ErbB2-PI3K-AKT pathway. It suppresses cell adhesion. EMP3 and ErbB2 co-espression is the most important marker of progression-free and metastasis-free patient survival (Wang et al., 2013).|
|Note||By a case-control study in 275 multiplex sibships on candidate genes and genomic regions with linkage to tumor suscpetibility and/or aggressiveness, the rs4893 variant displays a highly significant association, confirmed in a age-matched subsample. The EMP3 association, together with HPN: gene (19q11-q13.2), suggests the involvement of multiple genes within this genomic region in the prostate cancer susceptibility. The rs4893 allelic variant is significantly more frequent in prostate cancer patients compared to controls (Burmester et al., 2004).|
|Note||By RT-PCR, EMP3 displays high mRNA expression in gastric and colon cancer-derived cell lines (Fumoto et al., 2009b).|
|Note||By RT-PCR, EMP3 is significantly upregulated (2.5-fold) in keratoconus patients compared to a reference control group (Nielsen et al., 2005). EMP3 may have a potential role in the epithelial changes of the disease in agreement with the finding of blebs on the surface of KC corneas (Pfister and Burstein, 1977).|
|Note||Unknown fusion proteins..|
7. To be noted
|No genetic variants in the regulatory or coding regions responsible for EMP3 repression in cancer-derived cell lines without EMP3 hypermethylation or for EMP3 overexpression in other cancer-derived cell lines. An exception is the finding of the rs4893 allelic variant in the Caucasian A549 NSCLC cell line (Fumoto et al., 2009a) within a panel of 45 representative cancer cell lines. A Japanese- or Asian-population specific haplotype of three SNPs (rs8102349, rs8355 and rs11665) in non-coding regions is reported without association with the EMP3 expression levels (Fumoto et al., 2009a).|
|EMP3, a myelin-related gene located in the critical 19q13.3 region, is epigenetically silenced and exhibits features of a candidate tumor suppressor in glioma and neuroblastoma.|
|Alaminos M, Davalos V, Ropero S, Setien F, Paz MF, Herranz M, Fraga MF, Mora J, Cheung NK, Gerald WL, Esteller M.|
|Cancer Res. 2005 Apr 1;65(7):2565-71.|
|Chromosomal mapping of Tmp (Emp1), Xmp (Emp2), and Ymp (Emp3), genes encoding membrane proteins related to Pmp22.|
|Ben-Porath I, Kozak CA, Benvenisty N.|
|Genomics. 1998 May 1;49(3):443-7.|
|HNMP-1: a novel hematopoietic and neural membrane protein differentially regulated in neural development and injury.|
|Bolin LM, McNeil T, Lucian LA, DeVaux B, Franz-Bacon K, Gorman DM, Zurawski S, Murray R, McClanahan TK.|
|J Neurosci. 1997 Jul 15;17(14):5493-502.|
|Analysis of candidate genes for prostate cancer.|
|Burmester JK, Suarez BK, Lin JH, Jin CH, Miller RD, Zhang KQ, Salzman SA, Reding DJ, Catalona WJ.|
|Hum Hered. 2004;57(4):172-8.|
|Genomic and expression profiling of glioblastoma stem cell-like spheroid cultures identifies novel tumor-relevant genes associated with survival.|
|Ernst A, Hofmann S, Ahmadi R, Becker N, Korshunov A, Engel F, Hartmann C, Felsberg J, Sabel M, Peterziel H, Durchdewald M, Hess J, Barbus S, Campos B, Starzinski-Powitz A, Unterberg A, Reifenberger G, Lichter P, Herold-Mende C, Radlwimmer B.|
|Clin Cancer Res. 2009 Nov 1;15(21):6541-50. doi: 10.1158/1078-0432.CCR-09-0695. Epub 2009 Oct 27.|
|Identification of genes associated with the invasive status of human mammary carcinoma cell lines by transcriptional profiling.|
|Evtimova V, Zeillinger R, Weidle UH.|
|Tumour Biol. 2003 Aug-Sep;24(4):189-98.|
|EMP3 as a tumor suppressor gene for esophageal squamous cell carcinoma.|
|Fumoto S, Hiyama K, Tanimoto K, Noguchi T, Hihara J, Hiyama E, Noguchi T, Nishiyama M.|
|Cancer Lett. 2009a Feb 8;274(1):25-32. doi: 10.1016/j.canlet.2008.08.021. Epub 2008 Sep 26.|
|EMP3 as a candidate tumor suppressor gene for solid tumors.|
|Fumoto S, Tanimoto K, Hiyama E, Noguchi T, Nishiyama M, Hiyama K.|
|Expert Opin Ther Targets. 2009b Jul;13(7):811-22. doi: 10.1517/14728220902988549. (REVIEW)|
|The peripheral myelin protein 22 and epithelial membrane protein family.|
|Jetten AM, Suter U.|
|Prog Nucleic Acid Res Mol Biol. 2000;64:97-129. (REVIEW)|
|An evidence-based approach to establish the functional and clinical significance of copy number variants in intellectual and developmental disabilities.|
|Kaminsky EB, Kaul V, Paschall J, Church DM, Bunke B, Kunig D, Moreno-De-Luca D, Moreno-De-Luca A, Mulle JG, Warren ST, Richard G, Compton JG, Fuller AE, Gliem TJ, Huang S, Collinson MN, Beal SJ, Ackley T, Pickering DL, Golden DM, Aston E, Whitby H, Shetty S, Rossi MR, Rudd MK, South ST, Brothman AR, Sanger WG, Iyer RK, Crolla JA, Thorland EC, Aradhya S, Ledbetter DH, Martin CL.|
|Genet Med. 2011 Sep;13(9):777-84. doi: 10.1097/GIM.0b013e31822c79f9.|
|DNA hypermethylation and aberrant expression of the EMP3 gene at 19q13.3 in Human Gliomas.|
|Kunitz A, Wolter M, van den Boom J, Felsberg J, Tews B, Hahn M, Benner A, Sabel M, Lichter P, Reifenberger G, von Deimling A, Hartmann C.|
|Brain Pathol. 2007 Oct;17(4):363-70. Epub 2007 Jul 4.|
|Methylation profiling identifies 2 groups of gliomas according to their tumorigenesis.|
|Laffaire J, Everhard S, Idbaih A, Criniere E, Marie Y, de Reynies A, Schiappa R, Mokhtari K, Hoang-Xuan K, Sanson M, Delattre JY, Thillet J, Ducray F.|
|Neuro Oncol. 2011 Jan;13(1):84-98. doi: 10.1093/neuonc/noq110. Epub 2010 Oct 5.|
|A second locus for an axonal form of autosomal recessive Charcot-Marie-Tooth disease maps to chromosome 19q13.3.|
|Leal A, Morera B, Del Valle G, Heuss D, Kayser C, Berghoff M, Villegas R, Hernandez E, Mendez M, Hennies HC, Neundorfer B, Barrantes R, Reis A, Rautenstrauss B.|
|Am J Hum Genet. 2001 Jan;68(1):269-74. Epub 2000 Dec 7.|
|EMP3 overexpression is associated with oligodendroglial tumors retaining chromosome arms 1p and 19q.|
|Li KK, Pang JC, Chung NY, Ng YL, Chan NH, Zhou L, Poon WS, Ng HK.|
|Int J Cancer. 2007 Feb 15;120(4):947-50.|
|Regional localization of the human epithelial membrane protein genes 1, 2, and 3 (EMP1, EMP2, EMP3) to 12p12.3, 16p13.2, and 19q13.3.|
|Liehr T, Kuhlenbaumer G, Wulf P, Taylor V, Suter U, Van Broeckhoven C, Lupski JR, Claussen U, Rautenstrauss B.|
|Genomics. 1999 May 15;58(1):106-8.|
|A single nucleotide polymorphism in the Emp3 gene defines the H4 minor histocompatibility antigen.|
|Luedtke B, Pooler LM, Choi EY, Tranchita AM, Reinbold CJ, Brown AC, Shaffer DJ, Roopenian DC, Malarkannan S.|
|Immunogenetics. 2003 Aug;55(5):284-95. Epub 2003 Jul 4.|
|cDNA microarray analysis of genes associated with ERBB2 (HER2/neu) overexpression in human mammary luminal epithelial cells.|
|Mackay A, Jones C, Dexter T, Silva RL, Bulmer K, Jones A, Simpson P, Harris RA, Jat PS, Neville AM, Reis LF, Lakhani SR, O'Hare MJ.|
|Oncogene. 2003 May 1;22(17):2680-8.|
|Evaluation of a functional epigenetic approach to identify promoter region methylation in phaeochromocytoma and neuroblastoma.|
|Margetts CD, Morris M, Astuti D, Gentle DC, Cascon A, McRonald FE, Catchpoole D, Robledo M, Neumann HP, Latif F, Maher ER.|
|Endocr Relat Cancer. 2008 Sep;15(3):777-86. doi: 10.1677/ERC-08-0072. Epub 2008 May 22.|
|Promoter hypermethylation of the EMP3 gene in a series of 229 human gliomas.|
|Mellai M, Piazzi A, Caldera V, Annovazzi L, Monzeglio O, Senetta R, Cassoni P, Schiffer D.|
|Biomed Res Int. 2013;2013:756302. doi: 10.1155/2013/756302. Epub 2013 Sep 3.|
|Consensus statement: chromosomal microarray is a first-tier clinical diagnostic test for individuals with developmental disabilities or congenital anomalies.|
|Miller DT, Adam MP, Aradhya S, Biesecker LG, Brothman AR, Carter NP, Church DM, Crolla JA, Eichler EE, Epstein CJ, Faucett WA, Feuk L, Friedman JM, Hamosh A, Jackson L, Kaminsky EB, Kok K, Krantz ID, Kuhn RM, Lee C, Ostell JM, Rosenberg C, Scherer SW, Spinner NB, Stavropoulos DJ, Tepperberg JH, Thorland EC, Vermeesch JR, Waggoner DJ, Watson MS, Martin CL, Ledbetter DH.|
|Am J Hum Genet. 2010 May 14;86(5):749-64. doi: 10.1016/j.ajhg.2010.04.006. (REVIEW)|
|Altered expression of CLC, DSG3, EMP3, S100A2, and SLPI in corneal epithelium from keratoconus patients.|
|Nielsen K, Heegaard S, Vorum H, Birkenkamp-Demtroder K, Ehlers N, Orntoft TF.|
|Cornea. 2005 Aug;24(6):661-8.|
|Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma.|
|Noushmehr H, Weisenberger DJ, Diefes K, Phillips HS, Pujara K, Berman BP, Pan F, Pelloski CE, Sulman EP, Bhat KP, Verhaak RG, Hoadley KA, Hayes DN, Perou CM, Schmidt HK, Ding L, Wilson RK, Van Den Berg D, Shen H, Bengtsson H, Neuvial P, Cope LM, Buckley J, Herman JG, Baylin SB, Laird PW, Aldape K; Cancer Genome Atlas Research Network.|
|Cancer Cell. 2010 May 18;17(5):510-22. doi: 10.1016/j.ccr.2010.03.017. Epub 2010 Apr 15.|
|The normal and abnormal human corneal epithelial surface: a scanning electron microscope study.|
|Pfister RR, Burstein NL.|
|Invest Ophthalmol Vis Sci. 1977 Jul;16(7):614-22.|
|Epithelial membrane protein-2 and epithelial membrane protein-3: two novel members of the peripheral myelin protein 22 gene family.|
|Taylor V, Suter U.|
|Gene. 1996 Oct 10;175(1-2):115-20.|
|Epithelial membrane protein-1, peripheral myelin protein 22, and lens membrane protein 20 define a novel gene family.|
|Taylor V, Welcher AA, Program AE, Suter U.|
|J Biol Chem. 1995 Dec 1;270(48):28824-33.|
|Identification of novel oligodendroglioma-associated candidate tumor suppressor genes in 1p36 and 19q13 using microarray-based expression profiling.|
|Tews B, Felsberg J, Hartmann C, Kunitz A, Hahn M, Toedt G, Neben K, Hummerich L, von Deimling A, Reifenberger G, Lichter P.|
|Int J Cancer. 2006 Aug 15;119(4):792-800.|
|Potential significance of EMP3 in patients with upper urinary tract urothelial carcinoma: crosstalk with ErbB2-PI3K-Akt pathway.|
|Wang YW, Li WM, Wu WJ, Chai CY, Liu HS, Lai MD, Chow NH.|
|J Urol. 2014 Jul;192(1):242-51. doi: 10.1016/j.juro.2013.12.001. Epub 2013 Dec 10.|
|Epithelial membrane proteins induce membrane blebbing and interact with the P2X7 receptor C terminus.|
|Wilson HL, Wilson SA, Surprenant A, North RA.|
|J Biol Chem. 2002 Sep 13;277(37):34017-23. Epub 2002 Jul 9.|
|Epithelial membrane protein 3 is frequently shown as promoter methylation and functions as a tumor suppressor gene in non-small cell lung cancer.|
|Xue Q, Zhou Y, Wan C, Lv L, Chen B, Cao X, Ju G, Huang Y, Ni R, Mao G.|
|Exp Mol Pathol. 2013 Dec;95(3):313-8. doi: 10.1016/j.yexmp.2013.07.001. Epub 2013 Aug 3.|
|The H4b minor histocompatibility antigen is caused by a combination of genetically determined and posttranslational modifications.|
|Yadav R, Yoshimura Y, Boesteanu A, Christianson GJ, Ajayi WU, Shashidharamurthy R, Stanic AK, Roopenian DC, Joyce S.|
|J Immunol. 2003 May 15;170(10):5133-42.|
|EMP3 overexpression in primary breast carcinomas is not associated with epigenetic aberrations.|
|Zhou W, Jiang Z, Li X, Xu F, Liu Y, Wen P, Kong L, Hou M, Yu J.|
|J Korean Med Sci. 2009 Feb;24(1):97-103. doi: 10.3346/jkms.2009.24.1.97. Epub 2009 Feb 28.|
|This paper should be referenced as such :|
|Marta Mellai, Davide Schiffer|
|EMP3 (epithelial membrane protein 3)|
|Atlas Genet Cytogenet Oncol Haematol. 2015;19(12):694-699.|
|Free journal version : [ pdf ] [ DOI ]|
|On line version : https://atlasgeneticsoncology.usal.es/classic/Genes/EMP3ID44238ch19q13.html|
10. Other Leukemias implicated (Data extracted from papers in the Atlas) [ 1 ]
11. External links
|REVIEW articles||automatic search in PubMed|
|Last year publications||automatic search in PubMed|
|© Atlas of Genetics and Cytogenetics in Oncology and Haematology||indexed on : Thu Jan 17 18:54:11 CET 2019|
For comments and suggestions or contributions, please contact us firstname.lastname@example.org.